Mannan-binding lectin (MBL) plays an essential role in the innate immune system, being a first-line defense against a variety of pathogens. As a pattern recognition molecule, MBL binds to specific carbohydrate structures on the surface of bacteria, viruses, fungi, and parasites. This binding activates the lectin complement pathway, resulting in pathogen opsonization, inflammation, and direct lysis. Additionally, MBL stimulates phagocytosis by promoting microbe recognition and uptake by immune cells. Low levels or variant alleles of MBL are associated with enhanced risk of infection, autoimmune diseases, and inflammatory pathologies. In this review, we investigate MBL’s molecular mechanisms and physiological role, as well as its clinical relevance and therapeutic opportunities. Based on updated knowledge on immunology and genetics, we analyze how deficiencies in MBL affect immune responses and diseases. We speculate on the possibility of MBL-based therapies to cure immune-related diseases. Despite MBL’s important role in immunity, we are far from a comprehensive understanding of its interactions in the larger network of innate immunity. Generating therapeutic strategies that boost MBL function in immunocompromised hosts would be of interest.
K. Abosalif, Bi Bi Zainab Mazhari, M. Atif et al.· Journal of Pure and Applied...· 0 citations
Saudi Arabia faces a major tuberculosis (TB) challenge, potentially amplified by a large expatriate population from endemic areas, yet long-term national analyses remain limited. A retrospective analysis of Ministry of Health surveillance data was conducted for 2012–2024. Temporal trends were evaluated using segmented regression, while spatial heterogeneity across 20 health regions was assessed using burden and incidence analyses; distributions by sex, nationality, age, and TB type were examined. Future TB incidence rates were projected to 2029 using ARIMA and exponential smoothing (ETS) models; given the small number of annual observations, these projections are exploratory. A total of 37,477 TB cases were reported. A 2013 change point was followed by a decline of about 70 cases per year to 2024. Incidence fell during the 2020 pandemic and is currently around 7–8 cases per 100,000 population, nationally. Burden was concentrated in Jeddah and Riyadh, while incidence analyses additionally identified Jazan’s elevated population-adjusted notification rate. Cases were more frequent among males (67.5–79.7%) and adults aged ≥ 15 years (~ 97% of notifications with age data); non-Saudi residents accounted for 42.0-57.5%, exceeding 50% in several years. Pulmonary TB comprised 73.6–79.0% of cases. Exploratory forecasts projected broadly stable incidence to 2029, with wide prediction intervals. Although TB burden has declined since 2013, national incidence has shown little further reduction after 2020. Exploratory forecasts suggest broadly stable incidence through 2029, although considerable uncertainty remains. Strengthened surveillance, targeted screening, and region-specific interventions are needed to advance WHO End TB targets.
I. Alruwaili, Shandana Riaz, Hasan Ejaz et al.· BMC Infectious Diseases· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
